Liid Pharmaceuticals, Inc.
Building the Oligonucleotide Safeguard Platform Business
As of December, 2025
| City | Year of Establishment | Founder |
|---|---|---|
| Suita, Osaka | 2019 | Fumito Wada Mariko Hrada-Shiba |
| Partner VC | Latest round of Fundraising | Valuation |
|---|---|---|
| Greencore Co., Ltd. | Pre-Series A | JPY 1,253million |
- Contact Information: info@liidpharma.co.jp
- Website: Liid Pharmaceuticals, Inc.
Program name
Deep-Tech Startups Support Program
Research theme
Building the Oligonucleotide Safeguard Platform Business
Business Plan
The objective of this project is the commercialization of the BROTHERS technology platform, which enhances the safety of antisense oligonucleotide (ASO) drugs. This involves establishing the necessary CMC (Chemistry, Manufacturing, and Controls) framework for the PNA strand, which functions as the safeguard, and obtaining the essential data package required for pharmaceutical development support.
Research Outline
In this R&D project, we will develop "BROTHERS," an enhanced version of conventional antisense oligonucleotides (ASO). We aim to resolve the challenges associated with conventional ASOs by employing a PNA strand that functions as a safeguard. Furthermore, we will establish a drug development support business utilizing this technology by executing the following:
- Development of standard manufacturing processes (CMC) for BROTHERS
- Development of standard formulations and stability evaluation
- Acquisition of standard pharmacokinetic (PK/PD) profiles
| Phase | Business Area/Field | Research Period | Research Grant Amount |
|---|---|---|---|
| STS | Healthcare | 2025-2026FY | JPY 300 million |
Last Updated : April 21, 2026